Introduction
============

α-Synuclein oligomers have recently been indicated as 'a new hope' in the field of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies ([@awaa008-B48]; [@awaa008-B7]). The oligomeric species of α-synuclein consist in small aggregates of the protein that have not yet acquired a fibrillar conformation, which occur in the early stage of the pathology, preceding and probably triggering the formation of pale bodies and Lewy bodies. In this field, [@awaa008-B48] searched for oligomeric α-synuclein species in post-mortem brain from Parkinson's disease patients using the proximity ligation assay (PLA), an innovative and simple approach capable of detecting *in situ* protein interactions (e.g. protein dimerization). The resulting α-synuclein PLA signal was significantly more abundant in patients than in healthy control subjects, confirming the wide distribution of α-synuclein oligomers in Parkinson's disease-affected brains and suggesting the relevance of this approach for studying pathology progression starting from the early stage ([@awaa008-B48]).

Recently, Parkinson's disease has been redefined as a multisystem disorder not limited to the CNS (reviewed in [@awaa008-B13]; [@awaa008-B34]). Several clues led to this statement. First, the prodromic stage of Parkinson's disease is often characterized by autonomic non-motor symptoms including constipation and sweating disturbance ([@awaa008-B11]; [@awaa008-B33]; [@awaa008-B35]). Furthermore, the presence of pathological α-synuclein inclusions was confirmed not only along the enteric nervous system ([@awaa008-B63]) and in the autonomic ganglia ([@awaa008-B17]), but also in other body regions ([@awaa008-B5]; [@awaa008-B27]; [@awaa008-B8]). Second, pure autonomic failure, a syndrome characterized by autonomic symptoms without motor features and due to neurodegeneration of neurons in sympathetic ganglia with α-synuclein-positive Lewy body-like inclusions ([@awaa008-B55]), frequently evolves into Parkinson's disease or multiple system atrophy. Furthermore, ^123^I-MIBG myocardial scintigraphy is able to distinguish Parkinson's disease both from healthy subjects, with 95% sensitivity and 88.9% specificity ([@awaa008-B54]), and from atypical parkinsonism, with a diagnostic sensitivity of 89.5% ([@awaa008-B50]), as the loss of postganglionic sympathetic fibres occurs exclusively in Parkinson's disease and dementia with Lewy bodies patients, not in those affected by multiple system atrophy ([@awaa008-B35]). The same denervation was observed in the autonomic structures of the skin, i.e. vessels and sweat glands in patients with Parkinson's disease ([@awaa008-B15]; [@awaa008-B42]). This alteration translates into the autonomic dysfunction that may be observed in the prodromal stage of Parkinson's disease, including sweating disturbance ([@awaa008-B59]).

Given the increasing body of evidence related to defects of the autonomic nervous system in Parkinson's disease, many studies have investigated the distribution of α-synuclein pathology in the peripheral nervous system looking for an early marker of the pathology and focusing mainly on the presence and accumulation of total and phosphorylated α-synuclein (reviewed in [@awaa008-B52]). To date, the only study concerning α-synuclein oligomers in the autonomic nervous system was performed using the PLA technique in gastrointestinal biopsies of patients with Parkinson's disease and healthy control subjects ([@awaa008-B49]). Despite the positive outcome of peripheral PLA staining, the detection of α-synuclein oligomers in gastrointestinal samples was not considered adequate to diagnose or predict Parkinson's disease.

In this scenario, the aim of the present study was to search for α-synuclein oligomers in the peripheral nervous system by focusing on skin biopsies, which constitute a simple and minimally invasive model to detect α-synuclein-related pathology in living patients ([@awaa008-B66]; [@awaa008-B19]; [@awaa008-B28]). As studies on monozygotic twins offer the opportunity to control for many potential confounders encountered in general population studies \[i.e. differences in genetic background, early-life environmental exposure, age and gender ([@awaa008-B10])\], we conducted a comparative analysis in a cohort of Parkinson's disease patients and healthy subjects including a noteworthy subgroup of monozygotic twins discordant for the disease.

Materials and methods
=====================

Patients and clinical assessment
--------------------------------

The case-control study population consisted of 105 subjects: 29 consecutive healthy controls, 38 consecutive Parkinson's disease patients and 19 couples of monozygotic twins discordant for the disease (total number of Parkinson's disease cases, *n = *57; total number of healthy controls, *n = *48). All subjects were enrolled at the Parkinson Institute (Milan, Italy) by neurologists experienced in movement disorders and contributed to the Parkinson Institute Biobank ([@awaa008-B25]). In twin pairs, monozygosity was confirmed by carrying out a genotyping scan of DNA on peripheral blood samples (2 ml each). Specifically, DNA was extracted using a commercial isolation kit, performing a quantitative fluorescent polymerase chain reaction (QF-PCR) as previously reported ([@awaa008-B24]). Patients and controls were balanced for age at assessment and gender. In addition to general demographic data, the following information was collected for all patients: disease duration, clinical rating of activities of daily living and motor symptoms \[using parts II and III of the Unified Parkinson's Disease Rating Scale (UPDRS), respectively ([@awaa008-B21])\], disease severity \[using the Hoehn and Yahr staging system ([@awaa008-B32])\], presence of constipation \[using Rome III criteria ([@awaa008-B2])\] and orthostatic hypotension \[if the patients required the use of specific medication and/or experienced a fall in systolic blood pressure of at least 20 mmHg and diastolic blood pressure of at least 10 mmHg within 3 min of standing ([@awaa008-B500]; [@awaa008-B14])\]. The demographic and clinical data of the investigated cohort are reported in [Table 1](#awaa008-T1){ref-type="table"}. In addition, the Composite Autonomic Symptom Score 31 (COMPASS 31) ([@awaa008-B56]; [@awaa008-B46]), a 31-item self-administered questionnaire addressing six domains of autonomic functions (orthostatic intolerance, vasomotor, secreto-motor, gastrointestinal, bladder, and pupillomotor), was administered to the study population (*n = *94; [Table 2](#awaa008-T2){ref-type="table"}).

###### 

Demographic and clinical data

  Variable                             Total PD cases   Total healthy controls   Consecutive idiopathic PD cases   Consecutive healthy controls   PD twins      Healthy twins
  ------------------------------------ ---------------- ------------------------ --------------------------------- ------------------------------ ------------- ---------------
  Male gender, *n* (%)                 38 (67)          26 (54)                  24 (63)                           12 (41)                        14 (74)       14 (74)
  Age at biopsy, years, mean (SD)      61.6 (10.8)      60.3 (12.0)              61.4 (9.9)                        58.9 (11.6)                    61.8 (12.6)   61.8 (12.6)
  Disease duration, years, mean (SD)   7.1 (5.6)        --                       7.4 (6.2)                         --                             6.4 (4.1)     --
  UPDRS part II score, mean (SD)       6.6 (5.1)        --                       6.1 (5.6)                         --                             7.4 (4.5)     --
  UPDRS part III score, mean (SD)      19.3 (12.4)      --                       20.2 (13.2)                       --                             17.6 (10.9)   --
  Hoehn and Yahr stage, mean (SD)      1.9 (0.7)        --                       2.0 (0.7)                         --                             1.8 (0.7)     --
  Orthostatic hypotension, *n* (%)     4 (7)            --                       4 (11)                            --                             0 (0)         --
  Constipation, *n* (%)                34 (60)          --                       22 (58)                           --                             12 (63)       --

PD = Parkinson's disease; SD = standard deviation.

###### 

COMPASS 31 data

  Domain                               Total PD cases   Total healthy controls   Consecutive idiopathic PD cases   Consecutive healthy controls   PD twins        Healthy twins
  ------------------------------------ ---------------- ------------------------ --------------------------------- ------------------------------ --------------- ---------------
  Orthostatic intolerance, mean (SD)   5.64 (9.71)      0.65 (3.01)              4.25 (8.06)                       0.00 (0.00)                    8.00 (11.85)    1.56 (4.58)
  Vasomotor, mean (SD)                 0.54 (1.19)      0.17 (0.67)              0.55 (1.17)                       0.07 (0.33)                    0.53 (1.25)     0.32 (0.95)
  Secreto-motor, mean (SD)             4.12 (4.06)      1.30 (2.10)              3.48 (3.92)                       1.71 (2.23)                    5.19 (4.18)     0.71 (1.80)
  Gastrointestinal, mean (SD)          5.99 (4.07)      3.74 (3.23)              5.44 (4.12)                       3.57 (3.59)                    6.91 (3.92)     3.97 (2.74)
  Bladder, mean (SD)                   1.63 (1.71)      1.16 (1.51)              1.60 (1.54)                       0.8 (1.38)                     1.70 (2.01)     1.67 (1.58)
  Pupillo-motor, mean (SD)             1.46 (1.39)      0.76 (1.03)              1.57 (1.41)                       0.8 (0.84)                     1.26 (1.38)     0.70 (1.27)
  Total, mean (SD)                     19.38 (14.1)     7.78 (6.30)              16.89 (12.12)                     6.95 (5.68)                    23.58 (16.54)   8.93 (7.08)

PD = Parkinson's disease.

Skin biopsy
-----------

Volar forearm skin biopsies were fixed in Zamboni solution for 24 h at 4°C. Then the samples were paraffin-embedded and sliced in 3-μm thick serial sections using a microtome (MR2258, Histoline), and processed as follows: (i) one section per patient was stained with haematoxylin and eosin to verify the presence of the dermal autonomic structures we were interested in, i.e. blood vessels, arrector pilorum muscles and sweat glands; (ii) one section for each sample underwent immunohistochemistry assays to assess the presence of total α-synuclein within the synaptic terminal targeting the autonomic structures of the skin; and (iii) three sections for each sample underwent the PLA procedure.

Proximity ligation assay and immunofluorescence
-----------------------------------------------

### Probe conjugation

Experiments were performed using a Duolink^®^ kit (Sigma-Aldrich), as previously described ([@awaa008-B48]). According to the manufacturer's instructions, 1 mg/ml rabbit anti-α-synuclein antibody S3062 (SynS3062, Sigma-Aldrich; directed to human α-synuclein, amino acids 111--132) was separately conjugated to the Probemaker oligonucleotides MINUS and PLUS. After probe conjugation, the resulting dilution of α-synuclein antibody was 1:20 of the original stock concentration.

### Procedure

After deparaffinization and rehydration, 3-μm sections from skin biopsies were pretreated in 10% formic acid (10 min), then a 20-min blocking step was unrolled with 1% bovine serum albumin (BSA) in 0.01 M phosphate-buffered saline (PBS) plus 0.1% Triton™ X-100 for 30 min. Subsequently, sections were incubated with α-synuclein-PLUS and α-synuclein-MINUS probes (1:100 in PLA diluent) and mouse anti-synaptophysin (Dako, clone DakSynap, 1:100) for 2 h at 37°C. The amplification reaction was accomplished by serial incubation with: (i) ligase in Duolink^®^ ligation solutions for 1 h at 37°C; and (ii) polymerase in Duolink^®^ amplification reagents that were added with the secondary antibody donkey anti-mouse conjugated to Alexa Fluor^®^ 568 (Molecular Probes) for 2 h at 37°C. Finally, samples were counterstained with TO-PRO^®^-3 (Molecular Probes; 1:1000, 10 min) and mounted using Mowiol^®^+DABCO^®^.

To confirm the specificity of probe-conjugated SynS3062, positive controls were obtained by staining mesencephalic brain sections of four patients with Parkinson's disease, which had notable antigenicity for α-synuclein and present Lewy body pathology, and by comparing them to brain sections of three control subjects ([Supplementary Fig. 1](#sup1){ref-type="supplementary-material"}). Negative controls were carried out omitting one of the two α-synuclein probes.

### Image acquisition and data analysis

Images including synaptophysin-positive autonomic structures (sweat glands, arrector pilorum muscles and arterioles) were collected at × 60 magnification (1024 × 1024) with a water-immersion 40 × objective, using a Leica Sp8 confocal microscope equipped with an Argon laser coupled with a Hybrid Detector (used to acquire PLA signal), a diode-pumped solid-state laser coupled with a photomultiplier tube and a helium/neon mixed gas laser coupled with a Hybrid Detector. For each sample, five-step images were collected, reconstructed in a *z*-stack and analysed with ImageJ software (NIH). We conducted the quantitative analysis in all the specimens containing the sweat gland (*n = *105) that displayed the greatest quantity of synaptic terminals, while the qualitative analysis was performed on arrector pilorum muscles (*n = *23 for overall controls; *n = *21 for Parkinson's disease) and arterioles (*n = *10 for overall controls; *n = *12 for Parkinson's disease). The presence of α-synuclein oligomers was rated as the area of PLA signal within synapses (synaptophysin-positive), normalized for synaptic density. The synaptic localization of PLA signal was assessed by the superimposition of the mask of the synaptophysin-positive red channel and the PLA-positive green channel. Furthermore, synaptic density was evaluated as the ratio between the synaptophysin-positive area (corresponding to total synaptic terminals) and the total area of the sweat gland (as previously described by [@awaa008-B42]). The score obtained was used in statistical analysis. All procedures were performed blind to the disease (Parkinson's disease versus healthy controls) and twin status (consecutive versus twins).

Statistical analysis
--------------------

Continuous variables are described as mean and standard deviation (SD) or median and interquartile range (IQR) according to normality of distribution. Dichotomous data are reported as counts and percentages, as appropriate. The primary end point of the study was the comparison of PLA density score between consecutive Parkinson's disease patients and consecutive healthy controls. It was performed using the Mann-Whitney test. Therefore, a multivariable model (with PLA score analysed on log scale) was built to adjust for age, gender and twin status. Three supportive comparisons were performed: (i) consecutive Parkinson's disease cases versus Parkinson's disease twins; (ii) consecutive healthy controls versus healthy twins; and (iii) affected twins versus healthy twins. This last comparison was performed using Wilcoxon's test (non-parametric test for paired data). Similar between-group comparison was considered for the analysis of COMPASS 31 scores. Comparison of dichotomous variables was conducted using Fisher's exact test. Then, receiver operating characteristic (ROC) curves were plotted to determine the best cut-off in terms of sensitivity and specificity in discriminating Parkinson's disease cases from controls. The positive predictive value (PPV) and the area under the curve (AUC) as a measure of overall performance were calculated accordingly. The association between PLA scores and clinical parameters (disease duration, UPDRS part II and III scores, Hoehn and Yahr stage, COMPASS 31 and secreto-motor domain of COMPASS 31), as well as that between PLA area, i.e. the area covered by PLA staining inside synaptic terminals and synaptic density, was investigated in Parkinson's disease patients with the calculation of Spearman's rank correlation coefficients (ρ). Finally, independent variables \[Model 1, disease status and PLA staining (\>96); Model 2, disease status and twin status\] associated with autonomic failure (COMPASS 31 total score and secreto-motor domain subscore) were investigated using linear regression analysis. The analysis was performed with the Stata 15.1 software (StataCorp). A two-tailed *P*-value \< 0.05 was considered statistically significant.

Ethical approval
----------------

The study was performed in agreement with the principles of the Declaration of Helsinki. Subjects participated to the Parkinson Institute Biobank, approved by Local Ethics Committee. Written informed consent was obtained from all subjects. Human brain samples (controls and Parkinson's disease cases) were obtained from Nervous Tissue Bank of Milan. Written informed consent was obtained prior to acquisition of tissue from all patients.

Data availability
-----------------

The datasets used and analysed during the current study are available from the corresponding author upon reasonable request.

Results
=======

PLA signal in skin biopsies increases in Parkinson's disease compared to healthy controls
-----------------------------------------------------------------------------------------

First, we assessed the specificity of the probe-conjugated-SynS3062 PLA technique in our experimental conditions and carried out the PLA technique in substantia nigra of human brain sections of control subjects ([Supplementary Fig. 1A and E](#sup1){ref-type="supplementary-material"}) and patients with Parkinson's disease ([Supplementary Fig. 1B and F](#sup1){ref-type="supplementary-material"}). PLA signal was absent in 3/3 controls ([Supplementary Fig. 1A and E](#sup1){ref-type="supplementary-material"}), while it provided both a particular dot-like pattern around pale bodies and widespread staining in the neuronal cell bodies of Parkinson's disease samples ([Supplementary Fig. 1B and F](#sup1){ref-type="supplementary-material"}). Total α-synuclein staining, which was assessed by classical immunohistochemistry, was instead present both in controls ([Supplementary Fig. 1C and G](#sup1){ref-type="supplementary-material"}) and cases ([Supplementary Fig. 1D and H](#sup1){ref-type="supplementary-material"}). Thus, widespread PLA staining, which was present in 8% of the neuronal cell bodies analysed (*n = *91), indicates that PLA specifically recognizes the oligomeric form of α-synuclein, which represents the hallmark of the early stage of the pathology. Furthermore, the lack of PLA staining in the neuronal cell bodies of controls (*n = *90) indicates that PLA does not reveal physiological α-synuclein. PLA staining occurs only in pathological aggregates, as previously demonstrated by [@awaa008-B48].

The assay was then performed on skin samples. We initially confirmed the presence of total α-synuclein in all the samples analysed ([Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}; the specificity of S3062 antibody was verified in immunohistochemistry by preabsorption with purified α-synuclein, as described in the [Supplementary material](#sup1){ref-type="supplementary-material"} and shown in [Supplementary Fig. 3A--F](#sup1){ref-type="supplementary-material"}). Then, considering the localization of α-synuclein mainly at the synaptic level, we pursued a single-blind investigation for the presence of α-synuclein oligomers within the synaptic terminals of skin sections, which were specifically stained with an anti-synaptophysin antibody. This strategy enabled us to investigate exclusively the autonomic fibres in the skin based not only on their anatomy ([@awaa008-B64]; [@awaa008-B66]; [@awaa008-B29]) but also on the fact that the afferent sensitive terminals are synaptophysin-negative ([@awaa008-B41]; [@awaa008-B60]; [@awaa008-B31]). The synaptophysin staining provided a plentiful and distinctive dot-like signal, highlighting the presence of synaptic terminals in all the autonomic structures of the skin ([Fig. 1A, C, E, G, I and J](#awaa008-F1){ref-type="fig"}). Negative control for PLA is shown in [Supplementary Fig. 3G](#sup1){ref-type="supplementary-material"}--I′. In control samples, little or no PLA signal was found within synaptophysin-positive fibres that make contacts with the observed structures ([Fig. 1A, B, E, F, I and J](#awaa008-F1){ref-type="fig"}). On the contrary, a greater amount of PLA-positive oligomeric species was present within the synaptic terminals targeting sweat glands ([Fig. 1C and D](#awaa008-F1){ref-type="fig"}), arrector pilorum muscle ([Fig. 1G and H](#awaa008-F1){ref-type="fig"}) and arterioles ([Fig. 1K and L](#awaa008-F1){ref-type="fig"}) in samples from Parkinson's disease patients. The most robust PLA signal was observed in sweat glands, probably due to the greater amount of synaptic terminals featuring this structure ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The staining pattern in twins discordant for Parkinson's disease was consistent with those of consecutive patients and healthy controls.

![**α-Synuclein-PLA staining within synaptic terminals in skin biopsies from controls and patients.** In sweat glands (**A**--**D**), arrector pilorum muscles (**E**--**H**) and blood vessels (**I** and **L**--**N**) the particular dot-like pattern of PLA (green) was detectable in Parkinson's disease patients (**C**, **D**, **G**, **H**, **M** and **N**; white arrows) within synaptic terminals (synaptophysin-positive, red), while it was mostly absent in healthy controls (**A**, **B**, **E**, **F**, **I** and **L**). Nuclei counterstained with TO-PRO^®^-3 (blue). *Insets* show ×2 magnified view of selected squared area. Scale bar = 20 μm. PD = Parkinson's disease.](awaa008f1){#awaa008-F1}

PLA score enables the distinction between Parkinson's disease patients and healthy subjects
-------------------------------------------------------------------------------------------

We aimed to quantify α-synuclein oligomers in the skin synaptic terminals. A first aspect to be considered is that, in accordance with a previously described reduction in the autonomic fibres in Parkinson's disease patients ([@awaa008-B15]; [@awaa008-B42]), we observed, by semiquantitative analysis, a decrease in the number of synaptic terminals targeting the autonomic structures analysed in 26.3% (*n = *15) of Parkinson's disease samples and 20% (*n = *21) of overall population samples ([Supplementary Fig. 4](#sup1){ref-type="supplementary-material"}), as revealed by the decrease in synaptophysin staining (consecutive controls versus overall Parkinson's disease population, *P = *0.009). Interestingly, we observed a comparable reduction in seven affected monozygotic twins (36.8%) and in four out of their seven healthy twins (21%), which is significantly greater than what was reported in the consecutive healthy cohort (3.4%). To normalize the amount of PLA signal for the presence of synaptic terminals, which reflects on the probability to find α-synuclein oligomers staining within, we performed a quantitative analysis based on the ratio between the area of PLA staining and the synaptic terminal density ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}), namely PLA score, as visualized in [Fig. 2](#awaa008-F2){ref-type="fig"}.

![**Analytical process in PLA score determination.** (**A**) Representative image of α-synuclein-PLA staining to be quantified. (**B**) Mask of synaptophysin-positive signal. (**C**) Superimposition of mask of **B** (yellow) and **A**. (**D**) Total sweat gland area. α-Synuclein-PLA staining (**A**) was evaluated as the ratio between the area of PLA signal within synaptic terminals and the synaptic density, defined as the ratio between the area of synaptophysin-positive signal (**B**, red area) and total sweat gland area (**D**, black area). *Inset* shows ×2 magnified view of selected squared area. Scale bar = 20 μm. PD = Parkinson's disease.](awaa008f2){#awaa008-F2}

The analysis of the median values of PLA scores ([Fig. 3](#awaa008-F3){ref-type="fig"}) detected a significantly higher signal in the total affected population than in the overall controls, despite a right-skewed distribution in both groups with a wider dispersion in patients. A significant difference was also found in consecutive patients versus consecutive healthy controls and in affected twins versus healthy twins. PLA scores were similar in consecutive Parkinson's disease patients and Parkinson's disease twins, and no significant difference was detected between consecutive healthy controls and healthy twins, although a 2.5-fold higher score was observed in healthy twins. Multivariate analysis confirmed the difference found between patients and overall controls (*P *\<* *0.001).

![**Box and whisker plots of PLA staining in the study population.** The box represents the median value (middle line) and the interquartile range (IQR; 25--75th percentile). The external lines extend from the minimum to the maximum value, excluding 'outside' (±1.5 times the IQR) and 'far out' (±3 times the IQR) values, which are displayed as separate points. PD = Parkinson's disease.](awaa008f3){#awaa008-F3}

Based on ROC analysis ([Fig. 4A](#awaa008-F4){ref-type="fig"}), a PLA score \>96 in the whole study population had the highest sensitivity and specificity in the identification of Parkinson's disease patients. However, as Parkinson's disease twins tended to present a higher PLA staining score, ROC curve was computed also in consecutive patients and consecutive healthy controls ([Fig. 4B](#awaa008-F4){ref-type="fig"}). The same cut-off presented an even higher performance in discriminating Parkinson's disease patients from controls. Using this threshold value, the proportions of subjects marked positively were: consecutive Parkinson's disease patients, 82%; consecutive healthy controls, 14%; Parkinson's disease twins, 89%; healthy twins, 47% \[versus consecutive healthy controls, *P = *0.019 (Fisher's exact test)\].

![**ROC curve analysis of PLA staining score in identifying Parkinson's disease patients.** The optimal criterion in the overall population (**A**) and in consecutive Parkinson's disease cases and consecutive healthy controls (**B**) is indicated along with its sensitivity, specificity, positive predictive value (PPV) and the area under the curve (AUC).](awaa008f4){#awaa008-F4}

We report no association between PLA score and clinical features of Parkinson's disease such as disease duration, UPDRS part II and III scores, Hoehn and Yahr stage and constipation. On the other hand, a mild linear correlation was found between PLA score and both COMPASS 31 total score ([Fig. 5A](#awaa008-F5){ref-type="fig"}) and secreto-motor domain subscore in the overall study population ([Supplementary Fig. 5A](#sup1){ref-type="supplementary-material"}). However, no correlation was found between COMPASS 31 and PLA scores in the subgroups of patients and controls. Between-group comparison of the scoring of autonomic failure mainly replicated the findings observed for the analysis of PLA score (COMPASS 31 total score, [Fig. 5B;](#awaa008-F5){ref-type="fig"} secreto-motor domain score, [Supplementary Fig. 5B](#sup1){ref-type="supplementary-material"}). Multivariate analysis confirmed that the observed differences in both COMPASS 31 ([Fig. 5C](#awaa008-F5){ref-type="fig"}) total and secreto-motor domain ([Supplementary Fig. 5C](#sup1){ref-type="supplementary-material"}) scores mainly depended on disease status and not on increased PLA staining. However, analogue bivariate regression models showed that total COMPASS 31 score was independently associated also with twin status (*P = *0.050; [Fig. 5D](#awaa008-F5){ref-type="fig"}), while no effect was found for secreto-motor domain (*P = *0.61; [Supplementary Fig. 5D](#sup1){ref-type="supplementary-material"}).

![**Autonomic function and PLA score.** (**A**) Spearman's rank correlation between Composite Autonomic Symptom Score 31 (COMPASS 31) and PLA (black dots, controls; white dots, patients). (**B**) Box and whisker plots of COMPASS 31 in the study population. (**C**) Box and whisker plots of COMPASS 31 in the study population by disease status and increased PLA staining according to linear regression analysis. (**D**) Box and whisker plots of COMPASS 31 in the study population by disease status and twin status according to linear regression analysis. For box and whisker plots: the box represents the median value (middle line) and the IQR (25--75th percentile); the external lines extend from the minimum to the maximum value, excluding 'outside' (±1.5 times the IQR) and 'far out' (±3 times the IQR) values, which are displayed as separate points. PD = Parkinson's disease.](awaa008f5){#awaa008-F5}

Discussion
==========

In this study, we aimed to (i) test the hypothesis that patients with Parkinson's disease are characterized by increased accumulation of α-synuclein oligomers in the synaptic terminals of the autonomic nerve fibres in skin biopsies; and (ii) disclose the role of putative genetic predisposition in contributing to synucleinopathy by evaluating the differential accumulation of oligomers in twins discordant for disease compared to consecutive unrelated Parkinson's disease patients and healthy controls. Although recent studies have investigated the distribution of α-synuclein oligomeric pathology in the CNS in Parkinson's disease ([@awaa008-B48]; [@awaa008-B53]) and multiple system atrophy ([@awaa008-B53]), proving that α-synuclein oligomers are significantly more abundant in affected brains than in controls, to date no evidence has been reported for the peripheral nervous system. Here, we disclose the significant increase in previously undetected α-synuclein oligomeric species within synaptic terminals of the autonomic nerve fibres in consecutive Parkinson's disease patients, compared to consecutive healthy subjects. This finding makes α-synuclein oligomers a reasonably good candidate for becoming a reliable biomarker, at least for sporadic forms of Parkinson's disease. Although no significant difference was detected between the median PLA score of consecutive healthy controls and of healthy twins, the increased prevalence of PLA-positive subjects among healthy twins enabled us to support the notion that genetic predisposition is an important but non-sufficient factor in the aetiology of the disease, and that additional environmental triggers are needed.

To date, peripheral α-synuclein oligomer pathology in Parkinson\'s disease has been studied by [@awaa008-B49], who investigated the distribution of oligomeric species of α-synuclein within nerve fibres of gastrointestinal samples from patients and healthy controls using the PLA technique. Surprisingly, they did not find any significant difference between the two cohorts, probably because of a methodology-related misinterpretation of data. The authors selected the number of nuclei as a normalization factor in the quantitative analysis, which does not reflect the quantity of nerve fibres in the tissue and flattens any possible difference. Furthermore, they selected calretinin as neuronal marker, although this calcium-binding protein identifies only a subpopulation of neurons ([@awaa008-B36]). On the contrary, another investigation on gastrointestinal samples performed using the protein misfolding cyclic amplification technique, proved to be able to distinguish between Parkinson's disease patients and healthy subjects based on the detection of α-synuclein aggregates ([@awaa008-B23]) and similar results were obtained by means of real-time quaking-induced conversion (RT-QuIC) on CSF ([@awaa008-B22]) and olfactory mucosa ([@awaa008-B16]), thus supporting the presence of α-synuclein pathology both in the peripheral nervous system and in fluids. Here we analysed skin biopsies and showed that 82% of consecutive Parkinson's disease patients displayed an increase in α-synuclein oligomers compared to consecutive healthy subjects, in 86% of whom oligomers were absent or present in low quantities. Previous studies investigated the distribution of α-synuclein in skin biopsy from living patients by immunohistochemical assays ([@awaa008-B62]), but different and controversial outcomes arose. Although total α-synuclein was detected both in patients with Parkinson's disease and control subjects, its amount was greater in patients ([@awaa008-B501]; [@awaa008-B28]). In addition, Gibbons and colleagues reported that the biopsy site does not affect the potency of total α-synuclein detection (90% sensitivity and specificity); for this reason we selected the biopsy site that is best-tolerated by the patients according to our clinical experience, namely the volar forearm. Further studies in the field suggested that the accumulation of phosphorylated α-synuclein in skin biopsy could constitute a high-sensitivity biomarker, which successfully enables the distinction between Parkinson's disease patients and healthy subjects ([@awaa008-B66]; [@awaa008-B19]; [@awaa008-B6]; [@awaa008-B39]). Study findings on phosphorylated α-synuclein deposits in skin biopsies have provided different ranges of sensitivity and specificity. [@awaa008-B19] reported a 100% specificity and a sensitivity that depends on the biopsy site (ranging from 31% in distal leg, to 100% in cervical site), whereas more recently, [@awaa008-B39] reported a value of 84% for both parameters, which is consistent with our results. The significance of phosphorylation in the biology and pathophysiology of the protein is controversial ([@awaa008-B61]). Despite some reports suggesting that phosphorylated α-synuclein promotes inclusion formation *in vitro* and in cellular models, other studies reported that, in human brain, phosphorylation of α-synuclein appears to take place in more advanced stages of disease ([@awaa008-B67]; [@awaa008-B43]). On the other hand, α-synuclein oligomerization was described as an early event in the pathology ([@awaa008-B48]; [@awaa008-B7]) that occurs independently of the phosphorylation process. Thus, our findings on α-synuclein oligomers reveal an intracellular event that may occur earlier than phosphorylation of α-synuclein aggregates. This is not in contrast to the current state of the art in the field, but rather it provides further information and insight into the mechanisms underlying onset and progression of α-synuclein pathology.

Our study cohort involves a group of twins discordant for the pathology never explored before, which has provided additional insights on the role played by genetic factors versus environmental factors in the development of Parkinson's disease. We report that 89% of affected twins exhibited an increased presence of α-synuclein oligomers, findings similar to the consecutive Parkinson's disease cohort. Interestingly, this pattern was also found in 47% of healthy twins, a significantly higher proportion than that in consecutive healthy subjects (14%). However, the comparison of median values showed only a trend towards significance, which was reasonably due to the skewness of data and the necessarily limited sample size, since the prevalence of Parkinson's disease and twin pregnancies are 1--2% and 0.3%, respectively ([@awaa008-B38]; [@awaa008-B30]). The prevalence of an increase of α-synuclein oligomers among our healthy cohort (14%) does not reflect the prevalence expected for Parkinson's disease (1% in the selected age group), whereas it is in accordance with the prevalence of incidental Lewy body disease (8--12%; [@awaa008-B4]; [@awaa008-B18]), which is characterized by the presence of α-synuclein inclusions in autoptic brain without clinical symptoms of either Parkinson's disease or dementia with Lewy bodies. Genetic predisposition has proved to be a key element in Parkinson's disease aetiology, both in genome-wide association studies ([@awaa008-B12]) and in a prospective study involving monozygotic twins ([@awaa008-B30]). In this last study, monozygotic twins displayed a concordance of 20% in developing Parkinson's disease. For these reasons, we can speculate that, among the percentage of healthy twins positive for α-synuclein-PLA (47%), not every subject is going to develop the pathology. Thus, the increased presence of α-synuclein oligomers within peripheral synaptic terminals of healthy twins does not seem to constitute a sufficient condition for the development of the pathology. However, the higher PLA score observed in healthy twins, compared to consecutive healthy controls, converges towards the evaluation of genetic predisposition as an important, but not independent factor responsible for Parkinson's disease, uncovering the key role of environmental factors, which are more likely to be shared in early and mid-life by twin pairs. Nonetheless, there is evidence that gene--environment interactions should also be also taken into account ([@awaa008-B45]).

Neither the meaning of the formation of α-synuclein oligomers in terms of neuronal health or disease, nor how this potentially contributes to α-synuclein pathology has been understood so far. On one side, the toxicity of the oligomeric species of α-synuclein is supported by numerous studies, both in *in vitro* and in cellular models ([@awaa008-B65]; [@awaa008-B40]), which point to the identification of several putative targets that could play crucial roles in triggering cell death in Parkinson's disease and, as a whole, in synucleinopathies. Among others, a dose-dependent increase in α-synuclein oligomerization has been indicated as the cause of axonal transport disruption, leading to synaptic terminal loss in an induced pluripotent stem cells model obtained from Parkinson's disease patients carrying α-synuclein gene duplication or E46K mutation ([@awaa008-B47]). An emerging target for α-synuclein in pathological processes is the microtubule cytoskeleton, given the evidence that α-synuclein interacts with microtubules and their dynamics, and that Parkinson's disease-linked mutations in α-synuclein corrupt this interaction and interfere with microtubule behaviour in neurons ([@awaa008-B9]). On the other side, α-synuclein aggregation has recently been proposed to be an epiphenomenon or a protective element, although 'these conceptual frameworks are difficult to resolve because of the inability to probe brain tissue in real time' ([@awaa008-B20]). An intriguing point is the presence of very small amounts of staining for α-synuclein oligomers observed in control brains ([@awaa008-B48]; [@awaa008-B53]) and the low percentage of positivity found in the autonomic nervous system of healthy patients, as revealed by our analyses. This indicates that the presence of small amounts of α-synuclein oligomers, insufficient to trigger the pathology, may be physiological, as suggested by the variability observed also in consecutive healthy controls. The correlation analyses between synaptic density and PLA staining---which appeared to be more consistent in Parkinson's disease patients ([Supplementary Fig. 6](#sup1){ref-type="supplementary-material"})---could potentially suggest a role for oligomer accumulation in synaptic degeneration and dysfunction. The detailed analysis of the chemical nature of α-synuclein oligomers in both patients and healthy controls might contribute to explain this picture. Indeed, two different species of α-synuclein oligomers, derived from familial α-synuclein mutants, have been reported ([@awaa008-B44]). These species exert a different grade of toxicity, mediated by a highly lipophilic element in the structure of α-synuclein, which promotes membrane interactions and disrupts lipid bilayer integrity ([@awaa008-B26]). This is consistent with the fact that α-synuclein mutations involved in familial Parkinson's disease (in particular A53T and E46K) are translated into vesicle interaction impairment ([@awaa008-B1]). In this context, [@awaa008-B3] indicated that native human α-synuclein acquires a helically folded tetrameric conformation, which undergoes little or no amyloid-like aggregation.

We further explored the potential relationship between skin α-synuclein oligomer deposition and the neurodegenerative process by taking clinical features into consideration. Similarly, although we found a mild correlation between PLA score and autonomic dysfunction (including measures of the secreto-motor domain) in the overall study population, no relationship was detected in the subgroup of patients. Besides, multivariate analysis disclosed that this relationship substantially depends on the disease status (Parkinson's disease versus healthy controls). Indeed, high PLA score is found both in Parkinson's disease patients showing autonomic defects as well as in patients not reporting any autonomic dysfunction. Similar results have been reported for the deposition of total α-synuclein in patients with and without autonomic defects ([@awaa008-B28]). Nonetheless, despite Parkinson's disease twins and consecutive Parkinson's disease patients displaying a comparable PLA score, multivariate analysis showed an independent worsening effect of twin status on autonomic dysfunction (COMPASS 31), which further enables one to argue that the amplification of the neurodegenerative burden is multifactorial (e.g. genetic, environmental, etc). In addition, we did not find any significant association between PLA score and clinical features of Parkinson's disease, including disease duration, the severity and disability of motor features (as assessed by the UPDRS part II and III scores and the Hoehn and Yahr stage). However, the causal relationship between the severity of Lewy body pathology and neuronal death in the pathophysiology of Parkinson's disease is still to be clarified ([@awaa008-B58]; [@awaa008-B37]). Taken as a whole, the present cross-sectional study design does not enable us to infer a cause-effect relationship between PLA-staining and neuronal synaptic density and clinical features. Therefore, the present results should be interpreted cautiously as the hypothesis of a putative toxic effect of α-synuclein oligomers needs to be addressed in a prospective study.

In conclusion, in this work we report the first evidence of previously undetected α-synuclein oligomers in the autonomic nervous system of the skin and propose their quantitative analysis, which could be a reliable diagnostic biomarker for Parkinson's disease. Indeed, the sensitivity, specificity and positive predictive value of this parameter are similar to those of scintigraphy ([@awaa008-B57]; [@awaa008-B51]), which is already taken into consideration for diagnostic purposes. In addition, our findings in discordant twins suggest the existence of a genetic predisposition, which increases the probability of developing the pathology. However, our data do not unveil the true pathological meaning of the oligomers, as their presence in pathology could be necessary, but not sufficient, in triggering fibre and neuron degeneration. We believe that further investigation of this cohort could be helpful in uncovering the pathological mechanisms underlying Parkinson's disease.
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